The SARS-CoV-2 virus can infect specialized pacemaker cells that maintain the heart’s rhythmic beat, setting off a self-destruction process within the cells, according to a preclinical study co-led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and NYU Grossman School of Medicine.
Researchers at Weill Cornell Medicine have identified a key protein that induces the program to build specialized liver blood vessels. The discovery could lead to engineered replacement hepatic tissue to treat common liver diseases.
A Cornell collaboration crossing medicine, law, technology and communication is aiming to encourage the use of health care benefits by refugees in the U.S. – who often suffer poor health but are using these entitlements less than they have in the past.
Using cutting-edge techniques, researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have visualized the structure of a receptor targeted by an anti-cancer immunotherapy. The finding may help scientists improve this type of cancer treatment.
Students in the Weill Cornell Medical College Class of 2022 learned on national Match Day where they will be doing their internship and residency training – setting the stage for the next several years of their medical careers and lives.
Individual Candida albicans yeast strains in the human gut are as different from each other as the humans that carry them, and some C. albicans strains may damage the gut of patients with inflammatory bowel disease, according to a new study from researchers at Weill Cornell Medicine.
Tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target for immunity-boosting cancer treatments, according to a study from researchers at Weill Cornell Medicine and Albert Einstein College of Medicine.
Most patients with severe COVID who are put on ventilators regain consciousness after removal of respiratory support, but recovery may take weeks after the period of mechanical ventilation has ended, according to a new study.
Anti-Mullerian hormone, traditionally thought of as a passive byproduct of polycystic ovary syndrome, may actually play an active role in the disorder, according to new research.
